Search Results
Your search for Matthew Stenger matches 7653 pages
Showing 3401 - 3450Selinexor Plus Dexamethasone Studied in Triple-Class Refractory Multiple Myeloma
In a phase IIb study (STORM Part 2) reported in TheNew England Journal of Medicine, Ajai Chari, MD, of Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, and colleagues found that oral selinexor and dexamethasone were active in some patients with multiple myeloma refractory to prior...
Improving Communication With Older Patients Using Geriatric Assessment During Oncology Visits
In the COACH study, reported in JAMA Oncology, Supriya G. Mohile, MD, MS, and colleagues found that including geriatric assessment in oncology visits for older adults with advanced cancer improved patient and caregiver satisfaction with communication regarding aging-related concerns. Study Details...
Polatuzumab Vedotin Plus Bendamustine/Rituximab for Transplantation-Ineligible Relapsed or Refractory DLBCL
In a phase Ib/II trial reported in the Journal of Clinical Oncology, Laurie H. Sehn, MD, MPH, and colleagues found that the addition of polatuzumab vedotin to bendamustine/rituximab improved response rate and progression-free and overall survival among transplantation-ineligible patients with...
Presenting Symptoms and Cancer Stage at Diagnosis
In a population-based study reported in The Lancet Oncology, Koo et al found that presenting symptoms of cancer were mostly associated with stage earlier than stage IV, suggesting a benefit of symptom awareness campaigns based on common symptoms. As stated by the investigators, “Early diagnosis...
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
In a phase II trial reported in JAMA Oncology, Liu et al found evidence of the activity of combined nivolumab and bevacizumab in relapsed ovarian cancer, with activity appearing to be greater in platinum-sensitive disease. Study Details In the trial, 38 women with relapsed epithelial ovarian cancer ...
5-Year Efficacy Outcomes With Dabrafenib Plus Trametinib in BRAF-Mutated Metastatic Melanoma
As reported in The New England Journal of Medicine by Caroline Robert, MD, PhD, of the Institut Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, and colleagues, the long-term follow-up of the phase III COMBI-d and COMBI-v trials has shown a pooled 5-year overall survival rate of 34% ...
Long-Term Effects of Denosumab in Patients With Giant Cell Tumor of Bone
As reported by Chawla et al in The Lancet Oncology, long-term data from the final analysis of an international phase II study suggest that a favorable risk-benefit ratio is maintained over time with denosumab treatment of patients with giant cell tumor of bone. Benefit of denosumab was indicated in ...
Selinexor Plus Dexamethasone Studied in Triple-Class Refractory Multiple Myeloma
In a phase IIb study (STORM Part 2) reported in The New England Journal of Medicine, Ajai Chari, MD, of Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, and colleagues found that oral selinexor and dexamethasone were active in some patients with multiple myeloma refractory to prior...
Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine/Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma
In a single-center phase II trial reported in JAMA Oncology, Andrea Cercek, MD, and colleagues found that hepatic arterial infusion of floxuridine in combination with systemic gemcitabine/oxaliplatin produced high response and disease control rates and was associated with promising overall survival ...
Exercise Intolerance in Adult Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Ness et al found a high rate of exercise intolerance among adult survivors of childhood cancer, irrespective of exposure to cardiotoxic treatment. Exercise intolerance was associated with poorer overall survival. The study involved 1,041...
Lenalidomide vs Observation in Asymptomatic Smoldering Multiple Myeloma
In a phase III trial reported in the Journal of Clinical Oncology, Sagar Lonial, MD, and colleagues found that lenalidomide significantly improved progression-free survival vs observation in patients with intermediate- or high-risk smoldering multiple myeloma. As noted by the investigators,...
Prognostic Biomarkers in Triple-Negative Breast Cancer Treated With Adjuvant Doxorubicin/Cyclophosphamide
As reported in the Journal of Clinical Oncology by Priyanka Sharma, MD, and colleagues, biomarker analysis among women with triple-negative breast cancer treated with adjuvant doxorubicin/cyclophosphamide in the SWOG 9313c trial has confirmed a 44-gene DNA damage immune response signature and...
Bendamustine/Rituximab Followed by Yttrium Y-90 Ibritumomab Tiuxetan in Previously Untreated Follicular Lymphoma
In the phase II Fol-BRITe study reported in Clinical Cancer Research, Lansigan et al found that a short course of bendamustine/rituximab followed by consolidation with yttrium Y-90 ibritumomab tiuxetan (Y-90 ibritumomab tiuxetan) was associated with a high response rate and a high rate of...
Risk of Subsequent Malignant Neoplasms in Childhood Cancer Survivors After Treatment With Chemotherapy Alone
As reported in the Journal of Clinical Oncology by Turcotte et al, analysis of the Childhood Cancer Survivor Study Cohort showed that childhood cancer survivors treated with chemotherapy alone—particularly higher cumulative doses of platinum and alkylating agents—are at an increased risk of...
Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
On May 15, 2019, venetoclax was approved for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 Supporting Efficacy Data Approval was based on findings from the open-label phase III CLL14 trial (ClinicalTrials.gov...
Nivolumab vs Taxane Therapy in Refractory Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Ken Kato, MD, and colleagues, the phase III ATTRACTION-3 trial conducted in predominantly Asian patients has shown a survival benefit with nivolumab vs paclitaxel or docetaxel in patients with advanced esophageal squamous cell carcinoma who were refractory to...
Apalutamide Treatment for Metastatic Castration-Sensitive Prostate Cancer and Health-Related Quality of Life
In an analysis of the phase III TITAN trial reported in The Lancet Oncology, Neeraj Agarwal, MD, and colleagues found that that treatment with apalatuamide was associated with preserved health-related quality of life, including pain and fatigue outcomes, in patients with metastatic...
Acute Toxicity With Intensity-Modulated Fractionated Radiotherapy vs Stereotactic Body Radiotherapy for Prostate Cancer
In an analysis from the phase III PACE-B trial reported in The Lancet Oncology, Nicholas van As, MD, and colleagues found that shortened treatment courses with stereotactic body radiotherapy did not increase gastrointestinal or genitourinary acute toxicity vs intensity-modulated fractionated...
Dietary Fiber, Yogurt Consumption, and Lung Cancer Risk
In a pooled analysis reported in JAMA Oncology, Yang et al found that higher fiber and higher yogurt consumption were associated with significantly reduced risk of lung cancer. Study Details The analysis included 627,988 men (mean age = 57.9 years) and 817, 862 women (mean age = 54.8 years) from...
Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals
In a study reported in JAMA Oncology,1Jonathan M. Loree, MD, of BC Cancer, Vancouver, British Columbia, Canada, and colleagues found that race and race subgroup analyses were frequently not included in reported trials supporting U.S. Food and Drug Administration (FDA) oncology drug approvals...
CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
As reported in The Lancet Oncology by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, extended follow-up of the phase III CheckMate 214 trial has shown maintained survival benefit of first-line nivolumab/ipilimumab vs sunitinib among patients with...
Lorlatinib in Advanced ROS1-Positive NSCLC
As reported by Alice T. Shaw, MD, and colleagues in The Lancet Oncology, a phase I/II trial has shown overall and intracranial activity of the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib in patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Lorlatinib...
High-Dose Bevacizumab for Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
In a phase II trial reported in the Journal of Clinical Oncology, Plotkin et al found that high-dose bevacizumab induction therapy did not appear to produce better outcomes compared with lower-dose treatment in patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas. As...
Regional Disparities in Metastatic Breast Cancer Survival Between 1990 and 2011
In a study reported in Cancer, Judith A. Malmgren, PhD, and colleagues found marked regional differences in improvements in breast cancer–specific survival among women diagnosed with metastatic breast cancer between 1990 and 2011, with the best rates found in an institutional cohort. Study ...
ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AML
As reported in The New England Journal of Medicine by Perl et al, the phase III ADMIRAL trial showed improved overall survival with the oral FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib vs salvage chemotherapy in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia...
Is There a Difference in Breast Cancer Recurrence Rates After Surgery With Regional vs General Anesthesia?
In a trial reported in The Lancet, Sessler et al found no difference in breast cancer recurrence after surgery with regional anesthesia-analgesia using paravertebral block and propofol vs general anesthesia with the volatile anesthetic sevoflurane and opioid analgesia. They also found no difference ...
DNA Vaccine for Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
In a phase II study reported in the Journal of Clinical Oncology, McNeel et al found that a DNA vaccine (pTVG-HP) encoding prostatic acid phosphatase did not improve 2-year metastasis-free survival vs control treatment in patients with progressive, nonmetastatic, castration-sensitive prostate...
Outcomes in Patients With Early Breast Cancer and High 21-Gene Recurrence Score Treated With Adjuvant Chemotherapy Plus Endocrine Therapy: Secondary Analysis of TAILORx
In a secondary analysis of the phase III TAILORx trial reported in JAMA Oncology, Joseph Sparano, MD, and colleagues found that adjuvant chemotherapy plus endocrine therapy produced good 5-year outcomes among women with hormone receptor–positive, HER2-negative, axillary node–negative breast cancer...
Long-Term Follow-up of Patients With Nodular Lymphocyte–Predominant Hodgkin Lymphoma Treated in GHSG Trials
In an analysis reported in the Journal of Clinical Oncology, Eichenauer et al found that patients with newly diagnosed nodular lymphocyte–predominant Hodgkin lymphoma treated in German Hodgkin Study Group (GHSG) trials had good long-term outcomes overall. Study Details The analysis identified the...
ctDNA and Recurrence Risk After Surgery and Adjuvant Chemotherapy for Stage III Colon Cancer
In a cohort biomarker study reported in JAMA Oncology, Tie et al showed that the circulating tumor DNA (ctDNA)-positive status after surgery and chemotherapy was associated with an increased risk of disease recurrence in patients with stage III colon cancer. Study Details The Australian multicenter ...
Levofloxacin Prophylaxis During Treatment of Newly Diagnosed Multiple Myeloma
In the phase III TEAMM trial reported in The Lancet Oncology, Drayson et al found that prophylactic treatment with levofloxacin during the first 12 weeks of multiple myeloma treatment in newly diagnosed patients was associated with a significant reduction in first febrile episodes or death from any ...
Factors Influencing Freedom From Distant Recurrence in Premenopausal Women With Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a long-term analysis of the TEXT/SOFT trials reported in the Journal of Clinical Oncology, Pagani et al found that potential benefits of escalating adjuvant endocrine therapy beyond tamoxifen alone in preventing distant recurrence may be minimal in premenopausal women with hormone...
Patient-Reported Outcomes Observed With Durvalumab Treatment After Chemoradiotherapy for Stage III Unresectable NSCLC
As reported in The Lancet Oncology by Hui et al, no clinically important differences in patient-reported outcomes were observed among patients receiving durvalumab vs placebo after chemoradiation for stage III unresectable non–small cell lung cancer (NSCLC) in the phase III PACIFIC trial. The...
Postdiagnosis Use of Aspirin in Patients With Biliary Tract Cancer
In a study reported in a research letter in JAMA Oncology, Jackson et al found that postdiagnosis aspirin use was associated with significantly improved overall survival across biliary tract cancer types. Study Details The study involved 2,934 adult patients diagnosed with biliary tract cancer...
Association Between Prior Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy Outcomes
In a study presented in a brief report in JAMA Oncology, David J. Pinato, MD, PhD, and colleagues found that past but not concurrent use of broad-spectrum antibiotic therapy was associated with poorer treatment outcomes in patients receiving immune checkpoint inhibitors for various cancers in...
Long-Term Recurrence-Free Survival With the Addition of Adjuvant Trastuzumab to Chemotherapy in HER2-Positive Breast Cancer
Long-term follow-up analysis of the NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31 trials, reported in the Journal of Clinical Oncology by Chumsri et al, showed poorer recurrence-free survival in hormone receptor (HR)-negative vs HR-positive HER2-positive breast cancer, with the addition of...
Long-Term Follow-up of Salvage Short-Term ADT Plus Radiotherapy After Radical Prostatectomy
As reported in The Lancet Oncology by Carrie et al, the 112-month follow-up of the French phase III GETUG-AFU 16 trial has confirmed the initial 5-year report of the trial, which reported improved progression-free survival with the addition of short-term androgen-deprivation therapy (ADT) to...
Pretreatment Vitamin D Deficiency and Outcomes in Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Borchmann et al found that pretreatment vitamin D deficiency was associated with poorer progression-free and overall survival rates in patients receiving first-line treatment for Hodgkin lymphoma. Study Details The analysis involved 351...
MONARCH 2: Interim Analysis of Overall Survival With Abemaciclib/Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer
As reported in JAMA Oncology by George W. Sledge, Jr, MD, and colleagues, an interim analysis of overall survival in the phase III MONARCH 2 trial has shown a significant advantage for abemaciclib plus fulvestrant vs fulvestrant alone in women with advanced hormone receptor–positive, HER2-negative...
Leydig Cell Failure and Dysfunction and Associated Adverse Health Outcomes in Male Survivors of Childhood Cancer
In a retrospective analysis from the St. Jude Lifetime Cohort Study reported in the Journal of Clinical Oncology, Chemaitilly et al identified the prevalence of and risk factors for failure and dysfunction of Leydig cells, which are responsible for testosterone secretion, and associated adverse...
Panitumumab Plus Modified FOLFOXIRI for First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer
In the German phase II VOLFI trial reported in the Journal of Clinical Oncology, Modest et al found that panitumumab plus modified FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) used as first-line therapy improved the objective response rate in patients with RAS wild-type...
CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLC
As reported in The Lancet by Luis Paz-Ares, MD, and colleagues, an interim analysis of the phase III CASPIAN trial has shown an overall survival benefit with the addition of durvalumab to platinum (either cisplatin or carboplatin)/etoposide chemotherapy in the first-line treatment of...
Pembrolizumab for Patients With Advanced Adrenocortical Carcinoma
In a single-center phase II study reported in the Journal of Clinical Oncology, Raj et al found that pembrolizumab showed activity in advanced adrenocortical carcinoma. Study Details Thirty-nine patients with advanced adrenocortical carcinoma were enrolled in the study between February 2016 and...
Superoxide Dismutase Mimetic for Reducing Severe Oral Mucositis From Concurrent Radiotherapy and Cisplatin in Head and Neck Cancer
In a phase IIb trial reported in the Journal of Clinical Oncology, Anderson et al found that the superoxide dismutase mimetic GC4419 was effective in reducing the duration, incidence, and severity of severe oral mucositis in patients with head and neck cancer receiving concurrent radiotherapy and...
Relapse-Free Survival After Vismodegib Discontinuation in Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma
In a French retrospective study reported in the Journal of Clinical Oncology, Herms et al found that long-term response is frequently maintained in patients discontinuing vismodegib after complete remission of locally advanced basal cell carcinoma, and that responses can be achieved with vismodegib ...
Superoxide Dismutase Mimetic for Reducing Severe Oral Mucositis From Concurrent Radiotherapy and Cisplatin in Head and Neck Cancer
In a phase IIb trial reported in the Journal of Clinical Oncology, Anderson et al found that the superoxide dismutase mimetic GC4419 was effective in reducing duration, incidence, and severity of severe oral mucositis in patients with head and neck cancer receiving concurrent radiotherapy and...
Trifluridine/Tipiracil Survival Benefit for Patients With Metastatic Gastric Cancer Who Had or Had Not Undergone Prior Gastrectomy
In a subgroup analysis of the phase III TAGS trial (TAS-102 Gastric Study) reported in JAMA Oncology, David H. Ilson, MD, PhD, and colleagues found positive trends in survival benefit with trifluridine/tipiracil treatment vs placebo for patients with pretreated metastatic gastric cancer or...
Addition of Trilaciclib to Chemotherapy in Metastatic Triple-Negative Breast Cancer
In a phase II trial reported in The Lancet Oncology, Tan et al found that the addition of the cell-cycle inhibitor trilaciclib to gemcitabine/carboplatin chemotherapy did not reduce the duration or incidence of severe neutropenia during chemotherapy in women with triple-negative breast cancer. A...
Factors in Genetic Testing Decisions Among Women With a Personal and Family History of Breast Cancer
In a study reported in the Journal of Oncology Practice, Scott et al identified several factors that motivated breast cancer survivors with high genetic risk to undergo genetic testing and found that clinicians often failed to discuss all relevant factors in decision-making. Study Details The...
Swallowing-Related Quality of Life After Radiotherapy vs Surgery for Oropharyngeal Squamous Cell Carcinoma
In the phase II ORATOR trial reported in The Lancet Oncology, Anthony Nichols, MD, and colleagues found a statistical but not clinically meaningful improvement in swallowing-related quality of life outcomes 1 year after treatment with radiotherapy vs transoral robotic surgery and neck dissection...
